Bibliographic record
Abstract
Canada’s Drug Agency (CDA-AMC) recommends that Lazcluze plus Rybrevant be reimbursed by public drug plans for the treatment of locally advanced (not amenable to curative therapy) or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations if certain conditions are met. Lazcluze plus Rybrevant should only be covered to treat adults (≥ 18 years) with newly diagnosed NSCLC whose tumours have spread to other parts of the body, returned after treatment, or cannot be removed by surgery or chemoradiation; whose tumours harbour EGFR exon 19 deletions or L858R substitution mutations; and who are in relatively good health. Lazcluze plus Rybrevant should only be reimbursed for patients who have not had any prior anticancer treatment for advanced or metastatic disease, if prescribed by clinicians with expertise in treating NSCLC, and the cost of Lazcluze plus Rybrevant does not exceed the total cost of treatment with osimertinib plus platinum-based chemotherapy (PBC).
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.001 |
| Bibliometrics | 0.001 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.017 | 0.007 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".